IP Library Granted Patent US 10,376,500
Granted Patent B2
US 10,376,500 · App. 15/435,494 · Granted Aug 13, 2019

Gel containing pirfenidone

Inventors: José Agustin Rogelio Magaña Castro (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX); Juan Socorro Armendáriz Borunda (Mexico City, MX)
Assignee: CELL THERAPY AND TECHNOLOGY S.A. DE C.V.
A61K31/4418A61K9/0014A61K9/06A61K47/02A61K47/18A61K47/22A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,500
App. No.
15/435,494
Granted
Aug 13, 2019
Kind
B2
Abstract

The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.

Claims (9)

1. A method for treating fibrotic lesions in a patient in need thereof, the method comprising cutaneous administration to the patient of a Pirfenidone gel consisting of 8% Pirfenidone, 0.5% of a viscous agent, 20% of a solubilizer, 11.5% of a non ionic solubilizer, 0.5% of a conserving agent, 0.5% of a neutralizer agent and 59% of purified water, thereby treating the fibrotic lesions in the patient.

2. The method of claim 1 , wherein

(a) the viscous agent in the Pirfenidone gel is selected from the group consisting of a Carbomer 940, Carbomer Interpolymer Type A, a cellulose derivative, a gum, and a poloxamer;

(b) the solubilizer in the Pirfenidone gel is selected from the group consisting of N-methylpyrrolidone, ethyl alcohol, and propylene glycol;

(c) the conserving agent in the Pirfenidone gel is selected from the group consisting of diazolidinyl urea, iodopropynyl butylcarbamate, methylparaben, propylparaben, and mixes of these conserving agents; and

(d) the neutralizer agent in the Pirfenidone gel is selected from the group consisting of primary, secondary and tertiary mono-, bi-, and triethanolamine aliphatic amines, and a hydroxide alkaline metal.

3. The method of claim 2 , wherein the viscous agent in the Pirfenidone gel is Carbomer 940, the solubilizer is N-methylpyrrolidone, the conserving agent is diazolidinyl urea, and the neutralizer agent is triethanolamine.

4. The method of claim 2 , wherein the viscous agent in the Pirfenidone gel is Carbomer 940, the solubilizer is N-methylpyrrolidone, the conserving agent is iodopropynyl butylcarbamate, and the neutralizer agent is triethanolamine.

5. The method of claim 2 , wherein the hydroxide alkaline metal in the Pirfenidone gel is sodium hydroxide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2020
From: CELL THERAPY TECHNOLOGY S.A. DE C.V.
To: EXCALIBUR PHARMACEUTICALS, INC.
Reel/Frame 053418/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2017
From: MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; VÁZQUEZ CERVANTES, LAURA; ARMENDÁRIZ BORUNDA, JUAN SOCORRO
To: CELL THERAPY AND TECHNOLOGY, S.A. DE C.V.
Reel/Frame 042128/0793 →
Priority Claims (1)
MX MX/a/2007/009796 · Aug 14, 2007 · national
Continuity (3)
Division 13893626 · May 14, 2013
Division 12673304
Related Publication 20170216268A1 · Aug 3, 2017
Cited By (2)
US 12,667,561 US 12,702,713